Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 7
Submit an article Journal homepage
369
Views
18
CrossRef citations to date
0
Altmetric
Drug Evaluations

Omalizumab: overview of pharmacology and efficacy in asthma

Dennis Keith Ledford Professor of Medicine and Pediatrics, University of South Florida College of Medicine Internal Medicine, Division of Allergy and Immunology, 13000 Bruce B Downs Blvd, VAR 111D, Tampa, Florida 33612, USA; Chief, University Community Hospital, Allergy Section, 13801. Bruce B Downs Blvd, Tampa, Florida 33613, USA +1 813 972 7631; +1 813 558 9421; [email protected]
Pages 933-943 | Published online: 15 Jun 2009

Bibliography

  • Sullivan SD, Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008;63(6):670-84
  • Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002;109(Suppl B):S482-9
  • Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl 4):557-60
  • Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320(5):271-7
  • Knudsen TB, Thomsen SF, Nolte H, Backer V. A population-based clinical study of allergic and non-allergic asthma. J Asthma 2009;46(1):91-4
  • The ENFUMOSA, study group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003;22:470-7
  • Rabe K, Adachi K, Lai CK, et al. Worlwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114:40-7
  • Rabe K, Vermiere PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000;16:802-7
  • Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836-44
  • Rea HH, Scragg R, Jackson R, et al. A case-control study of deaths from asthma. Thorax 1986;41:833-9
  • Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the12 months following hospital admission for asthma. Int J Epidemiol 1992;21:737-44
  • Tough SC, Hessel PA, Ruff M, et al. Features that distinguish those who die from asthma from community controls with asthma. J Asthma 1998;35:657-65
  • Xolair (Omalizumab) prescribing information. In: Administration FD, editor, South San Francisco, CA: Genentech; 2007
  • Beck LA, Marcotte GV, Macglashan D, et al. Omalizumab-induced reductions in mast cell FcϵRI expression and function. J Allergy Clin Immunol 2004;114(3):527-30
  • Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170(6):583-93
  • Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101(7):1483-92
  • Macglashan D, Bochner B, Adelman D, et al. Down-regulation of FcϵRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158:12
  • Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcϵRI on basophils. J Allergy Clin Immunol 2004;113(2):297-302
  • Saini S, Macglashan D, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FCϵRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999;162:5624-30
  • Slavin R, Ferioli C, Tannenbaum SJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreaing pharmacokinetic concentrations. J Allergy Clin Immunol 2009;123(1):107-13
  • Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25. BioDrugs 2002;16(5):380-6
  • Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther 2003;45(1163):67-8
  • Xolair® (Omalizumab) for Subcutaneous Use-Genentech, Inc. Available from: http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf
  • Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632-8
  • Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-90
  • Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61
  • Holgate S, Bousquet J, Wenzel S, et al. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17(4):233-40
  • Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8
  • Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17
  • Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
  • Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59(7):701-8
  • Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91(2):154-9
  • Data on File: ALTO study, Genentech, Inc. (ClinicalTrials.gov Identifier: NCT00401596)
  • Buhl R. Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review. Respir Med 2003;97(2):123-9
  • Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002;110(5):e55. doi: 10.1542/peds.110.5.e55
  • Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36. Available from: http://pediatrics.aappublications.org/cgi/content/full/ 108/2/e36 [Last accessed 23 May 2009]
  • Silkoff PE, Romero FA, Gupta N, et al. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody. Pediatrics 2004;113(4):e308-12
  • Steiss JO, Strohner P, Zimmer KP, Lindemann H. Reduction of the total IgE level by omalizumab in children and adolescents. J Asthma 2008;45(3):233-6
  • Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120(6):1373-7
  • Allegra J, Lipton A, Harvey H, et al. Decreased prevalence of immediate hypersenstivity (atopy) in a cancer population. Cancer Res 1976;36:3225-6
  • Talbot-Smith A, Fritschi L, Divitini ML, et al. Allergy, atopy and cancer: A prospective study of the 1981 Busselton cohort. Am J Epidemiol 2003;157:606-12
  • Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007;120(4):972-3
  • Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006;96(4):624-7
  • Bargagli E, Madioni C, Olivieri C, et al. Churg-Strauss vasculitis in a patient treated with omalizumab. J Asthma 2008;45(2):115-6
  • Puechal X, Rivereau P, Vinchon F. Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med 2008;19(5):364-6
  • Ruppert AM, Averous G, Stanciu D, et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008;121(1):253-4
  • Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol 2008;122(1):217-8
  • Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007;144(2):155-8
  • Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007;119(5):1279-80
  • Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 2008;63(8):747-8
  • Cooper PJ, Ayre G, Martin C, et al. Geohelminth infections: a review of the role of IgE and assessment of potential risks of anti-IgE treatment. Allergy 2008;63(4):409-17
  • Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37(2):197-207
  • Hoskins G, Mcgowan C, Thomas G, et al. Identifying the characteristics and costs of treating ‘poorly controlled’ asthma patients [Abstract 641]. Am J Respir Crit Care Med 2001;18(Suppl 33):329s
  • Sullivan SD, Rasouliyan L, Russo PA, et al. TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in sever or difficult-to-treat asthma. Allergy 2007;62:126-33
  • Asche CV, Brixner DI, Oderda GM. Has the cost-effectiveness of Xolair (omalizumab) been underestimated? J Allergy Clin Immunol 2005;115(5):1095; author reply 1095-6
  • Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-53
  • Campbell JD, Spackman DE, Sullivan SD. Revisiting the cost-effectiveness of omalizumab. Allergy 2007;62(12):1469
  • Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22(9):1765-76
  • Hochhaus G, Brookman L, Fox H, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003;19(6):491-8
  • Miller TP, Reeves MJ. Lack of cost-effectiveness of omalizumab. J Allergy Clin Immunol 2005;115(2):429-30-1
  • Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004;114(2):265-9
  • Revicki D, Brown R, Dale P. Questioning the economic evaluation of omalizumab. J Allergy Clin Immunol 2008;121(6):1514-5
  • Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007;120(5):1146-52
  • Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004;125(4):1378-86
  • Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005;29(1):31-48
  • Brown R, Turk F, Groot M, Dale P. Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated asthma: adaptation of INNOVATE and ETOPA data to The Netherlands. Eur Respir J 2007;30(Suppl 51):194s
  • Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA). 2007 Available from: http://www.ginasthma.org [Last accessed 23 May 2009]
  • Expert Panel Report (EPR-3): guidelines for the Diangosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2008;120(5 Suppl):S94-138
  • Boushey HA. Experiences with monoclonal antibody therapy for allergic asthma. J Allergy Clin Immunol 2001;108(2 Suppl):S77-83
  • Lanier BQ. Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. Ann Allergy Asthma Immunol 2003;90(6 Suppl 3):13-5
  • Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.